ZA202309225B - Immunogenic fusion protein - Google Patents

Immunogenic fusion protein

Info

Publication number
ZA202309225B
ZA202309225B ZA2023/09225A ZA202309225A ZA202309225B ZA 202309225 B ZA202309225 B ZA 202309225B ZA 2023/09225 A ZA2023/09225 A ZA 2023/09225A ZA 202309225 A ZA202309225 A ZA 202309225A ZA 202309225 B ZA202309225 B ZA 202309225B
Authority
ZA
South Africa
Prior art keywords
amino acid
amino acids
acid sequence
fusion protein
immunogenic fusion
Prior art date
Application number
ZA2023/09225A
Other languages
English (en)
Inventor
Bo Pedersen Fischer Per
Original Assignee
Minervax Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minervax Aps filed Critical Minervax Aps
Publication of ZA202309225B publication Critical patent/ZA202309225B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2023/09225A 2021-03-29 2023-10-02 Immunogenic fusion protein ZA202309225B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21165674.9A EP4066854A1 (en) 2021-03-29 2021-03-29 Immunogenic fusion protein
PCT/EP2022/058309 WO2022207657A1 (en) 2021-03-29 2022-03-29 Immunogenic fusion protein

Publications (1)

Publication Number Publication Date
ZA202309225B true ZA202309225B (en) 2025-03-26

Family

ID=75277909

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/09225A ZA202309225B (en) 2021-03-29 2023-10-02 Immunogenic fusion protein

Country Status (12)

Country Link
US (1) US20240173394A1 (cg-RX-API-DMAC7.html)
EP (3) EP4066854A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024512722A (cg-RX-API-DMAC7.html)
KR (1) KR20230163500A (cg-RX-API-DMAC7.html)
CN (1) CN117120081A (cg-RX-API-DMAC7.html)
AU (1) AU2022248869A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023019757A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212987A1 (cg-RX-API-DMAC7.html)
IL (1) IL307256A (cg-RX-API-DMAC7.html)
MX (1) MX2023011502A (cg-RX-API-DMAC7.html)
WO (1) WO2022207657A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202309225B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4553166A1 (en) 2023-11-07 2025-05-14 MinervaX ApS Method for preparing a sample for analysis
EP4748392A1 (en) 2024-11-20 2026-05-27 MinervaX ApS Vaccine formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107458A0 (en) 1992-11-02 1994-02-27 Gen Hospital Corp Conjugate vaccine against group b streptococcus
EP0656014B1 (en) 1993-03-19 2003-05-14 LINDAHL, Gunnar Protein rib, a cell surface protein that confers immunity to many strains of the group b streptococcus; process for purification of the protein, reagent kit and pharmaceutical composition
US6426074B1 (en) 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
PT2144924T (pt) * 2007-04-16 2016-08-17 Minervax Aps Vacina de proteína de fusão
CA3001433A1 (en) 2015-10-21 2017-04-27 Minervax Aps Immunogenic fusion protein
WO2017114655A1 (en) * 2015-12-30 2017-07-06 Minervax Aps Immunogenic complex for eliciting protective immunity against group b streptococcus

Also Published As

Publication number Publication date
AU2022248869A9 (en) 2023-11-09
BR112023019757A2 (pt) 2023-10-31
US20240173394A1 (en) 2024-05-30
EP4786002A2 (en) 2026-08-05
CA3212987A1 (en) 2022-10-06
MX2023011502A (es) 2023-10-19
IL307256A (en) 2023-11-01
KR20230163500A (ko) 2023-11-30
EP4313134A1 (en) 2024-02-07
AU2022248869A1 (en) 2023-10-26
JP2024512722A (ja) 2024-03-19
WO2022207657A1 (en) 2022-10-06
EP4066854A1 (en) 2022-10-05
CN117120081A (zh) 2023-11-24

Similar Documents

Publication Publication Date Title
EA200870176A1 (ru) НОВЫЙ ПОВЕРХНОСТНЫЙ БЕЛОК HAEMOPHILUS INFLUENZAE (БЕЛОК E; pE)
DK2295065T3 (da) Modificeret varmechockprotein-antigenpeptidkompleks
CN103160530B (zh) 一种融合基因及其应用
JPH04506005A (ja) 破傷風トキシンフラグメントcの発現
RU2018122755A (ru) Слитые белки fmdv-e2 и их применение
CN102333539B (zh) 重组禽传染性鼻炎疫苗及其制备方法
CN107488234B (zh) 禽腺病毒Hexon与鸡传染性法氏囊病病毒VP2融合抗原、亚单位疫苗及其制备方法
MX2023011502A (es) Proteina de fusion inmunogenica.
DE60235021D1 (de) Rekombinante, 56 bzw. 82 kda grosse antigene aus gametozyten von eimeria maxima codierende nukleinsäuren und ihre verwendungen
RU2012149036A (ru) Векторы парапоксвируса, содержащие антиген вируса бешенства
WO2005083072A1 (ja) 大腸菌における豚丹毒菌表層防御抗原変異体の製造方法
MX2025013140A (es) Composiciones para el uso en el tratamiento del acne
CN102277374A (zh) 一种鸡传染性法氏囊病基因工程亚单位疫苗的制备和应用
JP2024512722A5 (cg-RX-API-DMAC7.html)
CN118420773A (zh) 一种重组蛋白纳米颗粒及其制备方法和在制备广谱抗流感病毒疫苗中的应用
RU2019115303A (ru) Вакцинные конструкты и их применения против инфекций стафилококка
WO2019062709A1 (zh) 一种重组牛血清蛋白成熟肽及其制备方法和应用
CN107974458A (zh) 表达猪丹毒杆菌重组蛋白GAPDH的基因gapdh及其重组大肠杆菌与应用
CN103524624B (zh) 新城疫病毒和鸭圆环病毒融合蛋白及其编码基因与应用
EP0404576A2 (en) Recombinant avipoxvirus
WO2022003719A3 (en) POLYPEPTIDE FRAGMENTS, IMMUNOGENIC COMPOSITION AGAINST SARS-CoV-2, AND IMPLEMENTATIONS THEREOF
CN108359682A (zh) 一种具有免疫保护作用的迟缓爱德华菌外膜蛋白PagC
CN103145854B (zh) 重组Tβ4-BP5融合肽、基因、工程菌及应用
WO2010097977A1 (ja) 豚丹毒・豚マイコプラズマ肺炎経口投与型多価ワクチン
JP3532510B2 (ja) 組換え豚丹毒菌防御抗原の回収精製法